Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.50 |
| ▸ | LTA4H | P09960 | 2/20 | 0.48 |
| ▸ | HTR2C | P28335 | 2/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.45 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | MMP3 | P08254 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | MMP8 | P22894 | 1/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | MMP14 | P50281 | 1/20 | 0.42 |
| ▸ | TEAD1 | P28347 | 2/20 | 0.41 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.40 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.40 |
| ▸ | LIPE | Q05469 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL894468 | 0.91 | GBA1 (0.59) | GBA1HTR2CSLC6A2SLC6A4TEAD1 | |
| Hydrochloric Acid SCHEMBL4773715 | 0.89 | GBA1 (0.58) | GBA1HTR2CSLC6A2SLC6A4TEAD1 | |
| SCHEMBL13279963 | 0.87 | MAOB (0.55) | GBA1HTR2CMAOBPRMT5 | |
| SCHEMBL6929847 | 0.85 | GBA1 (0.50) | GBA1HTR2CSLC6A4MMP2MMP3 | |
| Hydrochloric Acid SCHEMBL22462991 | 0.84 | GBA1 (0.51) | GBA1HTR2CSLC6A2SLC6A4TEAD1 | |
| SCHEMBL6922681 | 0.83 | GBA1 (0.54) | GBA1LTA4HSLC6A2SLC6A4 | |
| SCHEMBL28933802 | 0.81 | HTR2C (0.49) | GBA1HTR2CSLC6A2SLC6A4TEAD1 | |
| SCHEMBL8227791 | 0.81 | HTR2C (0.49) | GBA1HTR2CSLC6A2SLC6A4TEAD1 | |
| SCHEMBL7526770 | 0.81 | GBA1 (0.71) | GBA1LTA4HSLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL23632761 | 0.80 | HTR2C (0.50) | GBA1HTR2CSLC6A2SLC6A4TEAD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6518284-B2 | For inhibiting the serotonin and/or noradrenaline reuptake, and are useful as medicaments in disorders in which an increase of levels of those neurotransmitters is necessary | FAES, FABRICA ESPANOLA DE PRODUCTOS QUIMICOS Y FARMACEUTICOS S.A. (ES) | 2003-02-11 | — | — | US | claimed |
| US-20020038031-A1 | New 4 - substituted piperidines | ORJALES VENERO AURELIO (ES) | 2002-03-28 | — | — | US | claimed |
| EP-1002794-A1 | 4-[(Aryl)(aryloxy)methyl]piperidine derivatives and their use as serotonin and/or noradrenaline reuptake inhibitors | FAES, Fabrica Espanola de Productos Quimicos y Farmaceuticos, S.A. (ES) | 2000-05-24 | — | — | EP | claimed |
| US-6518284-B2 | For inhibiting the serotonin and/or noradrenaline reuptake, and are useful as medicaments in disorders in which an increase of levels of those neurotransmitters is necessary | FAES, FABRICA ESPANOLA DE PRODUCTOS QUIMICOS Y FARMACEUTICOS S.A. (ES) | 2003-02-11 | — | — | US | disclosed |
| US-20020038031-A1 | New 4 - substituted piperidines | ORJALES VENERO AURELIO (ES) | 2002-03-28 | — | — | US | disclosed |
| EP-1002794-A1 | 4-[(Aryl)(aryloxy)methyl]piperidine derivatives and their use as serotonin and/or noradrenaline reuptake inhibitors | FAES, Fabrica Espanola de Productos Quimicos y Farmaceuticos, S.A. (ES) | 2000-05-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020038031-A1 | New 4 - substituted piperidines | ADRA2C, ADRB2, ADRB1 | GBA1 1368/4885LTA4H 1953/4885HTR2C 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.